Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

NCT05690048 is registered in ClinicalTrials.gov with Michael Dill as lead sponsor.

NCT NCT05690048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05690048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
Lead sponsor
Michael Dill
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2025
Completion date
March 31, 2028
Enrollment
48 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma, immunotherapy